The DOI matches its Crossref record; 280 of the 280 references it cites were found in a registry or an index.
Inflammatory Bowel Disease: Mechanisms, Redox Considerations, and Therapeutic Targets
Open accessAbstract
Oxidative stress is thought to play a key role in the development of intestinal damage in inflammatory bowel disease (IBD), because of its primary involvement in intestinal cells' aberrant immune and inflammatory responses to dietary antigens and to the commensal bacteria. During the active disease phase, activated leukocytes generate not only a wide spectrum of pro-inflammatory cytokines, but also excess oxidative reactions, which markedly alter the redox equilibrium within the gut mucosa, and maintain inflammation by inducing redox-sensitive signaling pathways and transcription factors. Moreover, several inflammatory molecules generate further oxidation products, leading to a self-sustaining and auto-amplifying vicious circle, which eventually impairs the gut barrier. The current treatment of IBD consists of long-term conventional anti-inflammatory therapy and often leads to drug refractoriness or intolerance, limiting patients' quality of life. Immune modulators or anti-tumor necrosis factor α antibodies have recently been used, but all carry the risk of significant side effects and a poor treatment response. Recent developments in molecular medicine point to the possibility of treating the oxidative stress associated with IBD, by designing a proper supplementation of specific lipids to induce local production of anti-inflammatory derivatives, as well as by developing biological therapies that target selective molecules (i.e., nuclear factor-κB, NADPH oxidase, prohibitins, or inflammasomes) involved in redox signaling. The clinical significance of oxidative stress in IBD is now becoming clear, and may soon lead to important new therapeutic options to lessen intestinal damage in this disease. Antioxid. Redox Signal. 19, 1711–1747. I. Introduction II. Molecular Mechanisms of Intestinal Barrier Dysfunction in IBD A. Alteration of the apical junctional complex B. Impairment of intestinal antimicrobial peptides C. Impairment of receptor-mediated microbial recognition 1. TLRs and activation of redox-sensitive transcription factors 2. RIG-I-like receptors 3. NLRs and their modulation by ROS D. The role of the endothelium in IBD progression III. Pro-Inflammatory and Anti-Inflammatory Cytokines in IBD A. Cytokines produced by Th cells B. Cytokines produced by T-regulatory cells IV. The Main Genetic Polymorphisms Associated with IBD V. Redox Imbalance in IBD A. Antioxidant defenses in IBD 1. Alteration of redox couples in the IBD-affected intestinal tract 2. Impairment of enzymatic antioxidant defense in IBD 3. Antioxidant vitamins and antioxidant-related trace metals in IBD mucosa 4. Dietary polyphenols and inflammation of the gut mucosa B. Oxidative insult in IBD 1. RNS in IBD progression 2. ROS in IBD progression 3. The role of lipid oxidation end-products in IBD VI. Redox State-Related Transcription Factors in the Etiopathogenesis of IBD A. Nuclear factor-κB B. Nuclear factor-erythroid 2-related factor 2 VII. Therapeutic Considerations A. TNFα-mediated NF-κB signaling B. The IL-1 family and inflammasomes as ROS-dependent targets C. NADPH oxidase as target of the pathogen recognition pathway D. The mitochondrial target PHB E. Suitable dietary regimens in IBD patients F. Lipoxins and resolvins: new drug candidates for IBD treatment VIII. Conclusions
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
Interleukin-10-deficient mice develop chronic enterocolitis
Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., & Müller, W. (1993) · Cell · doi:10.1016/0092-8674(93)80068-p · Cited by 4,274
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Seth, R. B., Sun, L., Ea, C.-K., & Chen, Z. J. (2005) · Cell · doi:10.1016/j.cell.2005.08.012 · Cited by 3,329
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Nakahira, K., Haspel, J. A., Rathinam, V. A. K., Lee, S.-J., Dolinay, T., Lam, H. C., Englert, J. A., Rabinovitch, M., Cernadas, M., Kim, H. P., et al. (2011) · Nature Immunology · doi:10.1038/ni.1980 · Cited by 3,049
Coombes, J. L., Siddiqui, K. R. R., Arancibia-Cárcamo, C. V., Hall, J., Sun, C.-M., Belkaid, Y., & Powrie, F. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070590 · Cited by 2,710
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Cited by
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Tian, T., Wang, Z., & Zhang, J. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4535194 · Cited by 714
Pathophysiology of Inflammatory Bowel Disease: Innate Immune System
Saez, A., Herrero-Fernandez, B., Gomez-Bris, R., Sánchez-Martinez, H., & Gonzalez-Granado, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021526 · Cited by 580
Lazar, V., Ditu, L.-M., Pircalabioru, G. G., Gheorghe, I., Curutiu, C., Holban, A. M., Picu, A., Petcu, L., & Chifiriuc, M. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01830 · Cited by 525
Ferroptosis involves in intestinal epithelial cell death in ulcerative colitis
Xu, M., Tao, J., Yang, Y., Tan, S., Liu, H., Jiang, J., Zheng, F., & Wu, B. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2299-1 · Cited by 425
Sahoo, D. K., Heilmann, R. M., Paital, B., Patel, A., Yadav, V. K., Wong, D., & Jergens, A. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1217165 · Cited by 339
ROS in gastrointestinal inflammation: Rescue Or Sabotage?
Aviello, G., & Knaus, U. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13428 · Cited by 278
Redox signaling in the gastrointestinal tract
Pérez, S., Taléns-Visconti, R., Rius-Pérez, S., Finamor, I., & Sastre, J. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.048 · Cited by 273
Genetic disorders coupled to ROS deficiency
O’Neill, S., Brault, J., Stasia, M.-J., & Knaus, U. G. (2015) · Redox Biology · doi:10.1016/j.redox.2015.07.009 · Cited by 164
The Plasma Membrane: A Platform for Intra- and Intercellular Redox Signaling
Nordzieke, D. E., & Medraño-Fernandez, I. (2018) · Antioxidants · doi:10.3390/antiox7110168 · Cited by 90
Butyrate modulating effects on pro-inflammatory pathways in human intestinal epithelial cells
Elce, A., Amato, F., Zarrilli, F., Calignano, A., Troncone, R., Castaldo, G., & Canani, R. B. (2017) · Beneficial Microbes · doi:10.3920/bm2016.0197 · Cited by 81
Metadata
- Authors
- Biasi, F., Leonarduzzi, G., Oteiza, P. I., & Poli, G.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2013-11-10
- Volume
- 19
- Issue
- 14
- Pages
- 1711-1747
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W1988581085
- Cited by
- 300
- References
- 280
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.